Stavros G Drakos

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Stavros G Drakos sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting upper half by trial count

Stavros G Drakos: 2 sponsored US clinical trials, 2 recruiting.

Stavros G Drakos sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Acute Myocardial Infarction, with 1 trials.

Mid-pack sponsor footprint

Stavros G Drakos is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING

Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock

NCT05185492
RECRUITING NA

LVAD Conditioning for Cardiac Recovery

NCT03238690

Therapeutic Areas

Acute Myocardial Infarction 1
Cardiogenic Shock 1
Heart Failure 1

What is open in the Stavros G Drakos pipeline

2 recruiting of 2 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Acute Myocardial Infarction (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Stavros G Drakos: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Stavros G Drakos sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Stavros G Drakos1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Stavros G Drakos sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Stavros G Drakos sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stavros G Drakos page

2 registered trials is a research-attention snapshot, not an endorsement of Stavros G Drakos or any single study.

  • 2 of Stavros G Drakos's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Acute Myocardial Infarction is the condition Stavros G Drakos studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myocardial Infarction trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Stavros G Drakos pipeline card: 2 registered trials from official public datasets.Report a data error.